TIL

Company Overview — What Does Instil Bio, Inc. Do?

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio, Inc. (TIL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bronson Crouch and employs approximately 410 people. With a market capitalization of $54M, TIL is one of the notable companies in the Healthcare sector.

Instil Bio, Inc. (TIL) Stock Rating — Avoid (April 2026)

As of April 2026, Instil Bio, Inc. receives a Avoid rating with a composite score of 19.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TIL ranks #4,298 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Instil Bio, Inc. ranks #784 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TIL Stock Price and 52-Week Range

Instil Bio, Inc. (TIL) currently trades at $8.11. The stock lost $0.37 (4.3%) in the most recent trading session. The 52-week high for TIL is $42.79, which means the stock is currently trading -81.0% from its annual peak. The 52-week low is $5.67, putting the stock 43.0% above its annual trough. Recent trading volume was 23K shares, suggesting relatively thin trading activity.

Is TIL Overvalued or Undervalued? — Valuation Analysis

Instil Bio, Inc. (TIL) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.50x, versus the sector average of 2.75x.

At current multiples, Instil Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Instil Bio, Inc. Profitability — ROE, Margins, and Quality Score

Instil Bio, Inc. (TIL) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -75.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -42.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TIL Debt, Balance Sheet, and Financial Health

Instil Bio, Inc. has a debt-to-equity ratio of 79.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 39.53x, indicating strong short-term liquidity. Total debt on the balance sheet is $85M. Cash and equivalents stand at $6M.

TIL has a beta of 1.80, meaning it is more volatile than the broader market — a $10,000 investment in TIL would be expected to move 80.3% more than the S&P 500 on any given day. The stability factor score for Instil Bio, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Instil Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Instil Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-10.70. Net income for the quarter was $-86M. Operating income came in at $-93M.

In FY 2025, Instil Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-10.70. Net income for the quarter was $-71M. Operating income came in at $-79M.

In Q3 2025, Instil Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.01. Net income for the quarter was $-14M. Operating income came in at $-15M.

In Q2 2025, Instil Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.24. Net income for the quarter was $-21M. Operating income came in at $-23M.

Over the past 8 quarters, Instil Bio, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing TIL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TIL Dividend Yield and Income Analysis

Instil Bio, Inc. (TIL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TIL Momentum and Technical Analysis Profile

Instil Bio, Inc. (TIL) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

TIL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Instil Bio, Inc. (TIL) ranks #784 out of 838 stocks based on the Blank Capital composite score. This places TIL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TIL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TIL vs S&P 500 (SPY) comparison to assess how Instil Bio, Inc. stacks up against the broader market across all factor dimensions.

TIL Next Earnings Date

No upcoming earnings date has been announced for Instil Bio, Inc. (TIL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TIL? — Investment Thesis Summary

The quantitative profile for Instil Bio, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Instil Bio, Inc. (TIL) earns a Avoid rating with a composite score of 19.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TIL stock.

Related Resources for TIL Investors

Explore more research and tools: TIL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TIL head-to-head with peers: TIL vs AZN, TIL vs SLGL, TIL vs VMD.